Pleco Therapeutics, a clinical-stage biopharmaceutical company, has received positive feedback from the FDA regarding its Investigational New Drug (IND) development plan for PTX-252. PTX-252, an intravenous therapy for Acute Myeloid Leukemia (AML), is designed to remove heavy metals from the tumor microenvironment, thereby enhancing the function of the p53 tumor suppressor protein and increasing cancer cell sensitivity to chemotherapy. The FDA’s support for Pleco’s proposed development strategy follows the agency’s prior granting of Orphan Drug Designation to PTX-252 for AML treatment.
This positive Pre-IND meeting outcome is crucial for advancing PTX-252’s development. The FDA’s feedback provides a clear regulatory pathway, which can significantly reduce development time and costs. This expedited timeline offers hope for AML patients who currently have limited effective treatment options, potentially bringing a novel therapeutic approach to market sooner. The clarity provided by the FDA also de-risks the development process for investors, making the project more attractive for potential funding and partnerships.
The FDA provided constructive guidance on nonclinical and clinical study requirements for PTX-252. Pleco is co-developing PTX-252 with Hyloris Pharmaceuticals, a Belgian specialty pharmaceutical company. This collaboration combines Pleco’s expertise in oncology with Hyloris’s drug development capabilities, potentially accelerating the progress of PTX-252 towards clinical trials.
This positive interaction with the FDA paves the way for Pleco Therapeutics to submit a formal IND application. A successful IND submission would allow Pleco to initiate clinical trials, marking a significant milestone in the development of PTX-252 and potentially offering a new treatment avenue for patients with AML. This development also reinforces Pleco’s position as a company focused on innovative cancer therapies, particularly those enhancing existing treatment efficacy.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
